Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29735781 | 0.93 | HSD17B10 (0.48) | HSD17B10ALDH1A1CYP3A4TSHRPIK3CA | |
| SCHEMBL28602211 | 0.85 | CYP3A4 (0.46) | HSD17B10ALDH1A1CYP3A4TSHRPIK3CA | |
| SCHEMBL10707332 | 0.84 | ALDH1A1 (0.40) | HSD17B10ALDH1A1CYP3A4TSHRPDE4A | |
| SCHEMBL141445 | 0.83 | HSD17B10 (0.50) | HSD17B10ALDH1A1CYP3A4TSHRPIK3CA | |
| SCHEMBL10484543 | 0.82 | PDCD1 (0.47) | HSD17B10ALDH1A1KMT2ABRD4AKT2 | |
| SCHEMBL10493873 | 0.81 | HSD17B10 (0.43) | HSD17B10ALDH1A1CYP3A4TSHRPIK3CA | |
| SCHEMBL28845278 | 0.81 | HSD17B10 (0.48) | HSD17B10ALDH1A1CYP3A4TSHRPIK3CA | |
| SCHEMBL845162 | 0.80 | HSD17B10 (0.52) | HSD17B10ALDH1A1CYP3A4PDE4APDE4B | |
| SCHEMBL30866155 | 0.80 | HSD17B10 (0.52) | HSD17B10ALDH1A1CYP3A4PDE4APDE4B | |
| SCHEMBL28243656 | 0.79 | ALDH1A1 (0.42) | HSD17B10ALDH1A1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5981750-A | Solid-phase synthesis of codeine from morphine | THE BOARD OF REGENTS OF THE UNIVERSITY AND COMMUNITY COLLEGE SYSTEM OF NEVADA (US) | 1999-11-09 | — | — | US | claimed |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12208140-B2 | Targeted delivery to beta cells | THE BROAD INSTITUTE, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2021001727-A1 | SOLUTION PROCESSABLE METAL-ORGANIC FRAMEWORKS VIA SURFACE FUNCTIONALIZATION | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-01-07 | — | — | WO | disclosed |
| US-20200384115-A1 | TARGETED DELIVERY TO BETA CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-10 | — | — | US | disclosed |
| EP-3612232-A1 | TARGETED DELIVERY TO BETA CELLS | The Broad Institute, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195486-A1 | TARGETED DELIVERY TO BETA CELLS | THE BROAD INSTITUTE, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-8277776-B2 | Compositions for delivery of therapeutics and other materials | PHARMAIN CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8257682-B2 | Compositions for delivery of therapeutics and other materials | PHARMAIN CORPORATION (US) | 2012-09-04 | — | — | US | disclosed |
| US-8231859-B2 | Compositions for delivery of therapeutics and other materials | PHARMAIN CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-6204337-B1 | Solid-phase synthesis of codeine from morphine | THE BOARD OF REGENTS OF THE UNIVERSITY AND COMMUNITY COLLEGE SYSTEM OF NEVEDA | 2001-03-20 | — | — | US | disclosed |
| EP-1066228-A1 | PARALLEL COMBINATORIAL APPROACH TO THE DISCOVERY AND OPTIMIZATION OF CATALYSTS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051546-A9 | PARALLEL COMBINATORIAL APPROACH TO THE DISCOVERY AND OPTIMIZATION OF CATALYSTS AND USES THEREOF | HARVARD COLLEGE (US) | 1999-11-18 | — | — | WO | disclosed |
| US-5981750-A | Solid-phase synthesis of codeine from morphine | THE BOARD OF REGENTS OF THE UNIVERSITY AND COMMUNITY COLLEGE SYSTEM OF NEVADA (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1999051546-A1 | PARALLEL COMBINATORIAL APPROACH TO THE DISCOVERY AND OPTIMIZATION OF CATALYSTS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1998012156-A1 | COMBINATORIAL APPROACH FOR GENERATING NOVEL COORDINATION COMPLEXES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-03-26 | — | — | WO | disclosed |
| US-5650471-A | COPOLYMERIZING AN ALPHA-OLEFIN AND A CYCLOOLEFIN IN THE PRESENCE OF A CATALYST FORMED FROM A TRANSITION METAL COMPOUND AND AN ORGANIC ALUMINUM COMPOUND | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-22 | — | — | US | disclosed |
| WO-1997019082-A1 | SOLID-PHASE SYNTHESIS OF CODEINE FROM MORPHINE | THE BOARD OF REGENTS OF THE UNIVERSITY AND COMMUNITY COLLEGE SYSTEM OF NEVADA ON BEHALF OF THE UNIVERSITY OF NEVADA-RENO (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0729983-A2 | Process for the production of cycloolefin random copolymer | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| EP-0719803-A2 | Process for the production of cycloolefin random copolymer | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384115-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | HSD17B10 2139/4885ALDH1A1 3259/4885CYP3A4 4632/4885 |
| US-12208140-B2 | Targeted delivery to beta cells | IAPP, ZFR, ZC3H11A | HSD17B10 2139/4885ALDH1A1 3259/4885CYP3A4 4632/4885 |
| US-20250186593-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | HSD17B10 2139/4885ALDH1A1 3259/4885CYP3A4 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.